This Cancer Center Support Grant application from the University of Pittsburgh Cancer Institute, an NCI-designated Comprehensive Cancer Center, seeks support for years 22-26. The UPCI is organized as a matrix center that integrates cancer research, clinical care, and cancer outreach across the University of Pittsburgh and its affiliated health system, UPMC. The UPCI includes 348 members from 37 academic departments who have come together to work to reduce the burden of cancer through cancer-related basic, translational, clinical, behavioral, epidemiological, prevention and control research. Total annual extramural cancer research funding (direct costs) to UPCI was $109.5 million (peer-reviewed $95M, non-peer-reviewed $14.5M) on October 1, 2009 of which $42.5M was received from the National Cancer Institute. The commitment of UPCI to transdisciplinary cancer research is exemplified by the fact that its members lead three SPORE grants (lung, head and neck, and skin cancers), eight cancer-focused P01s, two Early Detection Research Network grants, and a phase I U01. The impact of the cancer research driven by UPCI and its members can be seen in the more than 4,400 unique publications by UPCI investigators from 2004-2009 of which 45% represent collaborative efforts (17% intra-programmatic, 20% inter-programmatic, and 8% both). The integration of investigators at the main University of Pittsburgh campus with clinicians from a unique clinical care network encompassing about 40 UPMC community cancer centers across Western Pennsylvania has enabled enhanced patient access to clinical trials throughout our catchment area in a highly productive way. In 2008 a total of 11,484 patients were entered in the cancer registry. During that same year 1,158 and 2,508 patients entered interventional and non-interventional clinical trials, respectively. It is noteworthy that in 2008 30% of accruals to interventional trials were to investigator-initiated trials and 40% of accruals to interventional trials took place at UPMC community cancer centers. This renewal application requests support for twelve scientific research Programs, fifteen Shared Facilities, Protocol-Specific Research Support, Protocol Review and Monitoring System, planning and evaluation activities, developmental funds, senior leadership, staff investigators, and administration.

Public Health Relevance

UPCI is a comprehensive Cancer Center focused on cancer research, education, and care. UPCI laboratory and clinical investigators work closely together to identify improved approaches for cancer prevention, diagnosis and treatment with the common goal of reducing the burden of cancer and improving cancer care for patients who are diagnosed with this disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA047904-26S1
Application #
8790784
Study Section
Special Emphasis Panel (ZCA1-RTRB-L (M1))
Program Officer
Lin, Alison J
Project Start
1997-09-10
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$110,216
Indirect Cost
$37,466
Name
University of Pittsburgh
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Sun, Weijing; Patel, Anuj; Normolle, Daniel et al. (2018) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer :
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Chartoumpekis, Dionysios V; Yagishita, Yoko; Fazzari, Marco et al. (2018) Nrf2 prevents Notch-induced insulin resistance and tumorigenesis in mice. JCI Insight 3:
Christner, Susan; Guo, Jianxia; Parise, Robert A et al. (2018) Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. J Pharm Biomed Anal 150:169-175
Laymon, Charles M; Minhas, Davneet S; Becker, Carl R et al. (2018) Image-Based 2D Re-Projection for Attenuation Substitution in PET Neuroimaging. Mol Imaging Biol 20:826-834
Benoist, Guillemette E; van der Meulen, Eric; van Oort, Inge M et al. (2018) Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. Ther Drug Monit 40:222-229
Singh, Krishna B; Hahm, Eun-Ryeong; Rigatti, Lora H et al. (2018) Inhibition of Glycolysis in Prostate Cancer Chemoprevention by Phenethyl Isothiocyanate. Cancer Prev Res (Phila) 11:337-346
Li, Chunlei; Song, Baobao; Santos, Patricia M et al. (2018) Hepatocellular cancer-derived alpha fetoprotein uptake reduces CD1 molecules on monocyte-derived dendritic cells. Cell Immunol :
Thakur, Prakash C; Miller-Ocuin, Jennifer L; Nguyen, Khanh et al. (2018) Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer. J Transl Med 16:190
Posluszny, Donna M; Bovbjerg, Dana H; Agha, Mounzer E et al. (2018) Patient and family caregiver dyadic adherence to the allogeneic hematopoietic cell transplantation medical regimen. Psychooncology 27:354-358

Showing the most recent 10 out of 1187 publications